Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Announces Closing of Offering and Partial Exercise of
Option to Purchase Additional Shares

Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, in which 5,374,755 shares of its ordinary shares were sold at an offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This resulted in total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, of approximately $50 million (EUR 45.9 million).

In addition, Nyxoah announced today that the underwriters of the Offering have exercised their option to purchase additional shares for 300,000 shares at the public offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This exercise will bring the total gross proceeds of the Offering to approximately $52.5 million (EUR 48.5 million) before deducting underwriting discounts and commissions and estimated offering expenses. The closing of the exercise of the option to purchase 300,000 additional shares is expected to occur on June 3, 2024, subject to the satisfaction of customary closing conditions.

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. Degroof Petercam acted as a co-manager.

The public offering in the United States was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-268955) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2023. Copies of the final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading “Risk Factors” in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer

IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000963842

Agriculture min.: WOAH officially recognized Egypt as free of African horse sickness “AHS”


Minister of Agriculture and Land Reclamation El Sayyed El Quseir said that the World Organization for Animal Health (WOAH) officially recognized Egypt as free of African horse sickness (AHS).

This was announced within the activities of the ninety-first session of the General Assembly of the members of the World Organization for Animal Health, who unanimously voted on the technical file submitted by the General Authority for Veterinary Services to prove that the country is free of the disease.

El Sayyed El Quseir stressed that this announcement comes as a culmination of the efforts of the Ministry of Agriculture aimed at developing livestock and supporting Egypt’s pioneering role at the regional and international levels in this field.

Source: State Information Service Egypt

EgyptAir operates 17 flights transporting thousands of pilgrims to Mecca


EgyptAir operated air bridge to facilitate pilgrimages to Mecca, EgyptAir will conduct 17 flights on Saturday for pilgrims heading to the Holy Land of Mecca.

The airline will organize 11 Cairo-Jeddah flights, 5 Cairo-Medina flights, 1 Cairo-Taif flight, 3 Conakry-Medina flights, and 2 Bamako-Medina flights.

These flights will transport pilgrims from various delegations, including those from the Ministry of Interior, the Ministry of Health, New Valley Solidarity, South Sinai, Al-Mina, as well as pilgrims from Fayoum and Al-Wadi, New, Sharqia, South and North Sinai, Cairo, Kafr El-Sheikh, transit, Bamako, and Conakry.

EgyptAir has released guidelines for pilgrims traveling from Egyptian airports to the Holy Lands for this year’s Hajj pilgrimage.

Source: State Information Service Egypt

Badael Company Invites to Join its Initiative, Sign a Pledge for a Smoke-Free Saudi Arabia


Riyadh: As Badael, a PIF Company, marks its first anniversary, coinciding with ‘World No Tobacco Day’ on 31 May, the company announced the launch of the ‘Clear the Air’ campaign. This initiative calls upon individuals, organizations, and government entities to unite in creating a smoke-free Saudi Arabia.

Badael aims to curb smoking by providing safer alternatives in line with the quality-of-life Vision 2030. The company is leading the cause to help one million Saudis quit smoking by 2028, thanks to the first-ever Saudi-made DZRT nicotine pouches manufactured in Saudi Arabia.

In its first year, Badael achieved significant milestones, establishing and expanding its manufacturing capacity while investing substantially in research and development to enhance its product range. The company has diversified its distribution channels surpassing one million e-commerce orders since its inception, helping around three hundred thousand people locally transition from tobacco to their products. These achievements are a te
stament to Badael’s commitment to public health, underscore the company’s steadfast dedication to its mission, and exemplify its commitment to future expansion and innovation.

As part of the ‘Clear the Air’ campaign, individuals, corporations, and government bodies are invited to sign the pledge for a smoke-free Saudi Arabia. This collective effort aims to significantly reduce tobacco use and improve the overall well-being of Saudi society. The pledge emphasizes raising awareness about the dangers of smoking, supporting quitters, protecting youth, promoting clean air, and safeguarding the environment.

Make a difference by visiting Badael’s website and signing the pledge (https://badaelcompany.com/en/thecause).

Tolga Sezer, Chief Executive Officer of Badael, stated that “World No Tobacco Day is a powerful reminder of the urgent need to foster a better future for the Kingdom. Supporting Vision 2030, Badael is leading the cause to switch smokers away from a very harmful habit with the help of reduced-risk alt
ernatives like DZRT nicotine pouches by 2028. As we commemorate this day, we launch the ‘Clear the Air’ campaign to emphasize the significance of our mission and rally everyone to join the cause. By signing the pledge, you commit to raising awareness about the dangers of smoking, supporting those who wish to quit, protecting our youth, advocating for clean air, and respecting our environment. Together, we can create a brighter, smoke-free future for all.”

Source: Saudi Press Agency

Saudi Minister of Health Meets with Chairman of World Economic Forum


Geneva, The Saudi Minister of Health Fahd bin Abdurrahman Al-Jalajel has met with Founder and Executive Chairman of the World Economic Forum, Professor Klaus Schwab.

This comes during the Minister’s visit to Geneva to attend the meetings of 77th session of World Health Assembly (WHA77).

During the meeting, the two sides discussed issues of common interest, including the ways to enhance cooperation in the health, economic and digital fields.

Source: Saudi Press Agency